文献速递神经肿瘤

小脑胶质瘤显微手术结局与预后分析:病理、分子标志物及新临床见解

Microsurgical outcomes and prognostic analysis of cerebellar gliomas; pathology, molecular biomarkers, and novel clinical insights: a retrospective study.
PubMed 文献 · J Neurooncol · 2026-04-15

该回顾性研究纳入2014至2024年单中心450例后颅窝(小脑)胶质瘤显微手术患者,分析解剖位置、切除程度与分子标志物对预后影响。全切除率74.9%,位置是主要手术预测因素,小脑半球80.7%至桥小脑角42.1%不等;分子关联异于幕上胶质瘤。结论认为位置与分子标志物互补,手术需适应脑干毗邻解剖,并依分子分型辅助治疗。

要点

  • 肿瘤位置是独立预后因素,小脑半球全切除率最高,桥小脑角区最低。
  • 经改良乙状窦后入路可提高桥小脑角区全切除率至57.1%,3年总生存67.3%。
  • 小脑胶质瘤IDH与TERT负相关微弱,IDH突变与1p/19q共缺失仅弱正相关。

核心结论

  • 小脑胶质瘤的位置与分子标志物是互补的核心预后因素,位置独立决定手术可行性与长期生存。
  • 针对脑干毗邻解剖定制手术,并结合分子指导的辅助治疗,可带来有意义的生存获益。

研究设计与样本

  • 单中心回顾性分析,纳入2014至2024年接受显微手术切除的450例后颅窝(小脑)胶质瘤患者。
  • 系统关联解剖定位、肿瘤体积、切除程度、分子谱(IDH1/2、1p/19q、MGMT、TERT、BRAF V600E)、围手术期并发症与长期生存。
  • 采用1:1倾向性评分匹配(PSM)分离全切除(GTR)与肿瘤生物学/解剖混杂的因果效应。

主要发现

  • 全切除(GTR)率为74.9%,位置为主要手术预测因素:小脑半球80.7% > 蚓部78.0% > 第四脑室58.2% > 桥小脑角区42.1%(P < 0.001)。
  • 桥小脑角区接受改良乙状窦后入路亚组GTR率提高至57.1%(8/14),3年总生存67.3%,较历史对照绝对提高≥25%。
  • 小脑胶质瘤中IDH与TERT经典负相关可忽略(r = -0.09,幕上肿瘤约r ≈ -0.7),IDH突变与1p/19q共缺失仅弱正相关(r = 0.19,P < 0.001)。

关键数值与推荐

  • 全切除率按位置分层:小脑半球80.7%、蚓部78.0%、第四脑室58.2%、桥小脑角区42.1%(P < 0.001)。
  • 桥小脑角区改良乙状窦后入路亚组GTR率57.1%(8/14),3年总生存67.3%。
  • 小脑胶质瘤IDH-TERT相关系数r = -0.09,IDH与1p/19q共缺失相关系数r = 0.19(P < 0.001)。
  • 推荐对IDH野生型低级别胶质瘤早期放疗,对TERT突变高级别胶质瘤强化全身治疗。

临床怎么用

  • 术前依据肿瘤位置评估手术可行性,桥小脑角区可考虑改良乙状窦后入路以提高切除率。
  • 术后分子分型指导辅助治疗:IDH野生型低级别胶质瘤考虑早期放疗,TERT突变高级别胶质瘤强化全身治疗。
  • 小脑胶质瘤的分子关联不同于幕上胶质瘤,不应直接套用幕上范式进行预后判断。

局限性

  • 单中心回顾性设计,桥小脑角区改良入路亚组样本量小(8/14),结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cerebellar gliomas are a descriptive subset of posterior fossa gliomas which presents unique clinical challenges due to their proximity to critical structures. OBJECTIVE: To establish a location-stratified, molecularly integrated clinical benchmark for posterior fossa gliomas (cerebellar gliomas as a descriptive subset), and to define subtype-specific pathways that address the unique biological and anatomical characteristics of these tumors, distinct from supratentorial glioma paradigms. This study sets location-specific microsurgical outcome evaluation as primary objective and independent prognostic factor identification and subtype-specific adjuvant therapy definition as secondary objective. METHODS: This retrospective analysis of 450 patients with posterior fossa gliomas (cerebellar gliomas) who underwent microsurgical resection at a single institution was performed between 2014 and 2024. Anatomical localization such as cerebellar hemisphere, vermis, fourth ventricle, cerebellopontine angle (CPA) region, tumor volumetrics, extent of resection, and molecular profiling such as IDH1/2, 1p/19q, MGMT, TERT, and BRAF V600E, as well as perioperative morbidity, and long-term survival were systematically correlated. 1:1 propensity score matching (PSM) was used to disentangle the causal effect of gross total resection (GTR) from tumor biology/anatomical confounding. RESULTS: Gross total resection (GTR) was achieved in 74.9% of patients, with location emerging as the dominant surgical predictor: cerebellar hemisphere (80.7%) > vermis (78.0%) > fourth ventricle (58.2%) > CPA region (42.1%) (P < 0.001). In the subgroup of CPA region patients who received the modified retrosigmoid approach, GTR rate was significantly improved to 57.1% (8/14), yielding a 3-year overall survival of 67.3% to a ≥ 25% absolute improvement over historical controls. Molecular correlations in cerebellar gliomas diverged from supratentorial patterns: the canonical inverse IDH-TERT correlation was negligible (r = -0.09 vs. r ≈ -0.7 in supratentorial tumors), and IDH mutation showed only weak positive correlation with 1p/19q codeletion (r = 0.19, P < 0.001). CONCLUSION: Cerebellar gliomas follow the principle that location and molecular biomarkers are complementary core prognostic factors, with location as an independent determinant of surgical feasibility and long-term survival. Surgical tailoring to brainstem-adjacent anatomy and molecularly guided adjuvant strategies—including early irradiation for IDH-wildtype LGGs and intensified systemic therapy for TERT-mutant HGGs—deliver meaningful survival gains.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Liu X, Zeng M, Zhang J, et al. Microsurgical outcomes and prognostic analysis of cerebellar gliomas; pathology, molecular biomarkers, and novel clinical insights: a retrospective study. J Neurooncol. 2026. PMID: 41981289. doi:10.1007/s11060-026-05568-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。